Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program, including the extended half-life cytokine DF6002 as a potential treatment for solid and hematological cancers.
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill Covid-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as the company assesses the plasma-based treatment in a Phase III study.
Argenx announced positive topline results from the company’s Phase III ADAPT clinical trial of efgartigimod for myasthenia gravis.
Prellis Biologics Inc. generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.
As researchers and physicians try to identify ways to effectively treat and prevent COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, some are studying whether high-dose intravenous immunoglobulin (IVIg) could work. IVIg is a common blood plasma product that is used to treat other immune disorders.
While the world waits for a vaccine against SARS-CoV-2 – the novel coronavirus that causes COVID-19 – one likely control and exit strategy is testing for immunity, or an antibody test.
